Ivermectin and Zuranolone: A Double Standard in the Literature

J Neurol Neurocrit Care, Volume 5(1): 1–2, 2022 Three recent publications illustrate the ongoing double standard concerning the effectiveness of ivermectin for treatment of early outpatient cases of COVID-19 infection. It seems to be true that ivermectin has no beneficial effect for seriously ill hospitalized patients – its potential utility is for reducing the frequency of transition from early mild outpatient cases to severely ill hospitalized cases. Lack of effectiveness inside hospitals does not prove a lack of effectiveness in outpatient populations.